Abelacimab achieved a ~80% reduction in venous thromboembolism versus a standard of care comparator in gold standard proof-of-concept efficacy study, indicating its potential in a range of thromboembolic disorders CAMBRIDGE, Mass., July 19, 2021 /PRNewswire/ — Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced final results from the Phase 2 […]